Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The purpose of Study TOC110977 is to demonstrate clinical superiority of Retapamulin
ointment, 1%, over placebo in patients with secondarily-infected traumatic lesions, which
includes secondarily-infected lacerations, abrasions and sutured wounds. Subjects 2 months of
age and older will be treated with topical retapamulin or placebo ointment twice daily for 5
days. The primary endpoint of this study is the clinical response at follow-up (Day 12-14;
7-9 days after the end of therapy) in the intent-to-treat clinical population.